Go to interview with Charles L Vogel, MD
Go to interview with Alisha Stein, RNC, BSN, OCN
Go to interview with G Thomas Budd, MD
Go to interview with Desiree Grogan, RPA-C
 
 
To listen to individual tracks now, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
     
Charles L Vogel, MD
Medical Director
Cancer Research Network Inc
Plantation, Florida
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Counseling patients about the rationale for adjuvant systemic therapy
Track 3 Factors used to estimate a patient’s risk of recurrence
Track 4 Adjuvant systemic therapy for ductal carcinoma in situ (DCIS)
Track 5 Selection of adjuvant systemic therapy
Track 6 Mechanisms of action and efficacy of common hormonal therapies
Track 7 Benefit of trastuzumab in management of HER2-positive disease
Track 8 Evolution and selection of adjuvant chemotherapeutic regimens
Track 9 Quality control with ER, PR and HER2 testing
Track 10 Strategies to ensure accurate ER, PR and HER2 testing
Track 11 Utility of the Oncotype DX™ assay in clinical decision-making
     
Alisha Stein, RNC, BSN, OCN
CNS/Research Coordinator
Cancer Research Network Inc
Plantation, Florida
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Counseling patients about adjuvant chemotherapy
Track 3 Alopecia, nausea and vomiting associated with adjuvant chemotherapy
Track 4 Clinical use of the Oncotype DX assay
Track 5 Patients’ willingness to undergo adjuvant chemotherapy for a modest potential benefit
Track 6 Use of predictive and prognostic tools to guide treatment decision-making
Track 7 Side effects of tamoxifen versus the aromatase inhibitors
Track 8 Potential benefits of nanoparticle albumin-bound (nab) paclitaxel
Track 9 Educating patients about the risks and benefits of adjuvant trastuzumab
Track 10 Importance of accurately assessing a patient’s cardiac history before treatment with trastuzumab
Track 11 Patient compliance with adjuvant trastuzumab
Track 12 Potential role of bevacizumab in the management of metastatic breast cancer
Track 13 Efficacy and tolerability of fulvestrant
     
G Thomas Budd, MD
Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western
Reserve University
Cleveland Clinic Foundation
Cleveland, Ohio
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Prognostic and predictive tools to assess the magnitude of benefit of adjuvant therapy
Track 3 Risk of cardiac toxicity associated with adjuvant anthracycline-based chemotherapy in elderly patients
Track 4 Case discussion: Young woman with ER-positive, node-negative breast cancer and low Oncotype DX recurrence score
Track 5 Adjuvant chemotherapy for patients with high-risk, node-negative disease
Track 6 SOFT trial: Adjuvant hormonal therapy for premenopausal patients with ER-positive disease
Track 7 Treatment for patients rendered amenorrheic after adjuvant chemotherapy
Track 8 Switching from tamoxifen to an aromatase inhibitor and duration of hormonal therapy
Track 9 Time course for breast cancer recurrence with ER-positive and ER-negative disease
Track 10 Side effects and tolerability of tamoxifen versus the aromatase inhibitors
Track 11 Benefit of adjuvant trastuzumab for patients with high-risk, node-negative, HER2-positive disease
Track 12 Delayed adjuvant trastuzumab and adjuvant trastuzumab monotherapy
Track 13 Incidence and monitoring of cardiac toxicity associated with adjuvant trastuzumab
Track 14 Clinical use of bevacizumab for the management of metastatic breast cancer
Track 15 Side effects and tolerability of bevacizumab
     
Desiree Grogan, RPA-C
Cancer Institute of Long Island
Great Neck, New York
  
  Click here to download the entire interview  
Track 1 Introduction
Track 2 Case discussion: A 72-year-old woman with ER-positive, PR-negative, HER2-positive, node-negative breast cancer
Track 3 Differences in patient decision-making regarding adjuvant systemic therapy
Track 4 Adjuvant hormonal therapy for patients with ER-positive, PR-negative disease
Track 5 Side effects of tamoxifen versus the aromatase inhibitors
Track 6 Incidence of gynecological and thromboembolic complications in patients taking tamoxifen
Track 7 Counseling patients about adjuvant aromatase inhibitors
Track 8 Selection of adjuvant chemotherapy for patients with high-risk, node-negative disease
Track 9 Increased fatigue associated with adjuvant dose-dense AC paclitaxel
Track 10 Incorporation of adjuvant trastuzumab into clinical practice
Track 11 Prophylactic growth factor support for patients receiving adjuvant chemotherapy
Track 12 Cardiac toxicity, alopecia, nausea and vomiting associated with anthracycline-based chemotherapy
Track 13 Neuropathy and other side effects associated with paclitaxel
Track 14 Infusion reactions with trastuzumab
Track 15 Time course for recovery from adjuvant chemotherapy